Search
Influenza A virus A/Hong Kong/4801/2014 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14436ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) hemagglutinin antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14437ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) hemagglutinin antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14438ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Phuket/3073/2013 BVR-1B hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14442ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14444ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14445ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB14449ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14460ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14461ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Singapore/GP1908/2015 IVR-180A (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14468ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen